HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Anton F H Stalenhoef Selected Research

Familial Combined Hyperlipidemia (Combined Hyperlipidemia, Familial)

6/2014Familial combined hyperlipidemia: from molecular insights to tailored therapy.
1/2010Familial combined hyperlipidemia is associated with alterations in the cholesterol synthesis pathway.
11/2008Adiponectin multimer distribution in patients with familial combined hyperlipidemia.
7/2008Paraoxonase (PON1) is associated with familial combined hyperlipidemia.
4/2007High plasma level of remnant-like particles cholesterol in familial combined hyperlipidemia.
3/2007Remnant particles are the major determinant of an increased intima media thickness in patients with familial combined hyperlipidemia (FCH).
1/2007Haplotype analyses of the APOA5 gene in patients with familial combined hyperlipidemia.
12/2005Elevated leptin levels in subjects with familial combined hyperlipidemia are associated with the increased risk for CVD.
11/2005Decreased adiponectin levels in familial combined hyperlipidemia patients contribute to the atherogenic lipid profile.
9/2004Thioredoxin interacting protein in Dutch families with familial combined hyperlipidemia.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Anton F H Stalenhoef Research Topics

Disease

17Atherosclerosis
02/2015 - 01/2002
13Cardiovascular Diseases (Cardiovascular Disease)
03/2015 - 03/2005
12Hyperlipoproteinemia Type II (Familial Hypercholesterolemia)
02/2015 - 12/2002
12Familial Combined Hyperlipidemia (Combined Hyperlipidemia, Familial)
06/2014 - 02/2002
8Inflammation (Inflammations)
10/2013 - 01/2002
8Insulin Resistance
02/2011 - 01/2002
5Hypertriglyceridemia
09/2012 - 11/2002
5Infections
01/2009 - 01/2002
4Rheumatoid Arthritis
10/2013 - 04/2007
4Dyslipidemias (Dyslipidemia)
04/2011 - 03/2003
4Hyperlipidemias (Hyperlipidemia)
05/2009 - 02/2002
3Obesity
02/2011 - 11/2005
3Coronary Disease (Coronary Heart Disease)
01/2009 - 12/2005
3Chronic Kidney Failure (Chronic Renal Failure)
11/2005 - 03/2003
2Coronary Artery Disease (Coronary Atherosclerosis)
09/2015 - 05/2002
2Xanthomatosis (Xanthoma)
08/2014 - 12/2013
2Pancreatitis
08/2014 - 09/2012
2Hyperlipoproteinemia Type III (Broad Beta Disease)
05/2009 - 02/2002
2Hemochromatosis (Bronze Diabetes)
01/2009 - 06/2006
2Hyperlipoproteinemias
02/2006 - 08/2004
2Metabolic Syndrome (Dysmetabolic Syndrome X)
12/2005 - 04/2003
1Rare Diseases (Rare Disease)
03/2015
1Homozygous Familial Hypercholesterolemia
08/2014
1Death (Near-Death Experience)
12/2013
1Abdominal Aortic Aneurysm
01/2009
1Carotid Stenosis (Carotid Artery Stenosis)
01/2009
1Peripheral Arterial Disease
01/2009
1Salmonella Infections (Salmonellosis)
01/2009
1Stroke (Strokes)
01/2009
1Iron Overload
01/2009
1Muscular Diseases (Myopathy)
12/2008
1Myositis (Idiopathic Inflammatory Myopathies)
12/2008
1Myocardial Infarction
08/2008
1Necrosis
11/2007
1Septic Shock (Toxic Shock Syndrome)
10/2007
1Sepsis (Septicemia)
04/2007
1Abscess
04/2007
1Wounds and Injuries (Trauma)
04/2007
1Glucose Intolerance
04/2007
1Hypertension (High Blood Pressure)
03/2007
1Abdominal Obesity
03/2007

Drug/Important Bio-Agent (IBA)

15oxidized low density lipoproteinIBA
09/2015 - 03/2003
15CholesterolIBA
12/2013 - 05/2002
13LipidsIBA
08/2014 - 02/2002
13Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA
04/2010 - 12/2002
11Lipoproteins (Lipoprotein)IBA
08/2014 - 04/2004
10Simvastatin (Zocor)FDA LinkGeneric
02/2015 - 12/2002
9Atorvastatin (Lipitor)FDA Link
02/2015 - 12/2002
9Triglycerides (Triacylglycerol)IBA
08/2014 - 11/2002
7LDL CholesterolIBA
09/2015 - 01/2004
6ApolipoproteinsIBA
03/2015 - 08/2004
6CytokinesIBA
10/2013 - 01/2002
6HDL CholesterolIBA
09/2012 - 05/2002
4Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
04/2009 - 02/2006
4Aryldialkylphosphatase (Paraoxonase)IBA
08/2008 - 03/2005
4C-Reactive ProteinIBA
04/2008 - 12/2002
4LDL Lipoproteins (beta Lipoproteins)IBA
06/2006 - 03/2003
3Apolipoproteins B (ApoB)IBA
03/2015 - 06/2004
3AdiponectinIBA
04/2009 - 11/2005
2LDL Receptors (LDL Receptor)IBA
03/2015 - 01/2009
2Ezetimibe (Zetia)FDA Link
04/2010 - 04/2008
2Insulin (Novolin)FDA Link
11/2009 - 09/2005
2Apolipoprotein E2IBA
05/2009 - 02/2002
2LeptinIBA
04/2009 - 12/2005
2Apolipoproteins E (ApoE)IBA
01/2009 - 08/2004
2IronIBA
01/2009 - 06/2006
2Proteins (Proteins, Gene)FDA Link
02/2006 - 09/2004
2Rosuvastatin Calcium (Crestor)FDA Link
12/2005 - 09/2005
2Lipid PeroxidesIBA
11/2005 - 01/2004
2CopperIBA
11/2005 - 01/2004
1Proprotein Convertase 9IBA
03/2015
1Annexin A5IBA
02/2015
1mipomersenIBA
08/2014
1BMS201038IBA
08/2014
1Intercellular Adhesion Molecule-1 (Intercellular Adhesion Molecule 1)IBA
10/2013
1Fibric Acids (Fibrates)IBA
09/2012
1InterleukinsIBA
02/2011
1Colesevelam Hydrochloride (Welchol)FDA Link
04/2010
1Apolipoprotein B-100 (Apo B 100)IBA
01/2010
1Pioglitazone (Actos)FDA Link
11/2009
1Glucose (Dextrose)FDA LinkGeneric
11/2009
1AdipokinesIBA
04/2009
1LipopolysaccharidesIBA
01/2009
1Ferritins (Ferritin)IBA
01/2009
1coenzyme Q10 (CoQ10)IBA
12/2008
1UbiquinoneIBA
12/2008
1EnzymesIBA
12/2008
1Toll-Like Receptor 4IBA
10/2007
1Transferrin (beta 2 Transferrin)IBA
06/2006
1Interleukin 1 Receptor Antagonist Protein (Anakinra)FDA Link
02/2006
1Messenger RNA (mRNA)IBA
02/2006
1Interleukin-6 (Interleukin 6)IBA
02/2006
1Coenzyme A (CoA)IBA
02/2006
1Interleukin-1beta (Interleukin 1 beta)IBA
02/2006

Therapy/Procedure

9Therapeutics
08/2014 - 12/2002
2Renal Dialysis (Hemodialysis)
11/2005 - 03/2003
1Intravenous Injections
01/2009
1Secondary Prevention
01/2009
1Vascular Surgical Procedures
01/2009
1Peritoneal Dialysis
11/2005